This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Clindamycin Hydrochloride

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221013

Version

6

Spl Product Data Elements

Clindamycin Hydrochloride Clindamycin Hydrochloride CLINDAMYCIN HYDROCHLORIDE CLINDAMYCIN SILICON DIOXIDE FD&C BLUE NO. 1 FD&C RED NO. 3 GELATIN LACTOSE MONOHYDRATE MAGNESIUM STEARATE TALC TITANIUM DIOXIDE BLUE (CAP) BLUE (BODY) CAPSULE Z;89 Clindamycin Hydrochloride Clindamycin Hydrochloride CLINDAMYCIN HYDROCHLORIDE CLINDAMYCIN SILICON DIOXIDE FD&C BLUE NO. 1 FD&C RED NO. 3 GELATIN LACTOSE MONOHYDRATE MAGNESIUM STEARATE TALC TITANIUM DIOXIDE BLUE (CAP) BLUE (BODY) CAPSULE Z;90 Clindamycin Hydrochloride Clindamycin Hydrochloride CLINDAMYCIN HYDROCHLORIDE CLINDAMYCIN SILICON DIOXIDE FD&C BLUE NO. 1 FD&C RED NO. 3 GELATIN LACTOSE MONOHYDRATE MAGNESIUM STEARATE TALC TITANIUM DIOXIDE BLUE (CAP) BLUE (BODY) CAPSULE Z;91

Application Number

ANDA065217

Brand Name

Clindamycin Hydrochloride

Generic Name

Clindamycin Hydrochloride

Product Ndc

70771-1136

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1136-1 in bottle of 100 Capsules Clindamycin Hydrochloride Capsules USP, 75 mg Rx only 100 Capsules NDC 70771-1137-1 in bottle of 100 Capsules Clindamycin Hydrochloride Capsules USP, 150 mg Rx only 100 Capsules NDC 70771-1183-1 in bottle of 100 Capsules Clindamycin Hydrochloride Capsules USP, 300 mg Rx only 100 Capsules Clindamycin HCL Capsules USP, 75 mg Clindamycin HCL Capsules USP, 150 mg Clindamycin HCL Capsules USP, 300 mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.